No evidence for an involvement of the P38 and JNK mitogen-activated protein in inflammatory bowel diseases

Digestive Diseases and Sciences

Volumn 51, Issue 8, 2006, Pages 1443-1453

  Malamut, Georgia ^a,b,c   Cabane, Candice ^d   Dubuquoy, Laurent ^a,b,c   Malapel, Mathilde ^a,b,c   Dérijard, Benoit ^d   Gay, Jérôme ^a,b,c   Tamboli, Cyrus ^a,b,c   Colombel, Jean Frédéric ^a,b,c   Desreumaux, Pierre ^a,b,c  

^a INSERM   (France)

^b UNIV LILLE   (France)

^c LILLE UNIVERSITY HOSPITAL   (France)

^d CNRS   (France)

Author keywords

Colitis; Inflammatory bowel disease; Intestinal inflammation; JNK MAPK; P38 MAPK; SB203580; TNBS

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; AMINOSALICYLIC ACID; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE P38; MOLECULAR MARKER; STEROID; STRESS ACTIVATED PROTEIN KINASE; TRINITROBENZENESULFONIC ACID;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CLINICAL ARTICLE; COLITIS; COLON MUCOSA; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; ENTERITIS; ENZYME ACTIVITY; FEMALE; HUMAN; INFLAMMATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; SCORING SYSTEM; SURVIVAL; THERAPY EFFECT;

EID: 33748164488     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-006-9116-2     Document Type: Article

References (38)

1. Ghosh S, Karin M (2002) Missing pieces in the NF-kappaB puzzle. Cell 109(Suppl):S81-S96
2. Barnes PJ, Karin M (1997) Nuclear factor-kappa B: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 15:1066-1071
3. Chen Z, Gibson TB, Robinson F, Silvestro M, Pearson G, Xu B, Wright A, Vanderbilt A, Cobb MH (2001) MAP kinases. Chem Rev 101:2449-2476
4. Pearson G, Robinson F, Beers Gibson T, Xu BE, Karandikar M, Berman K, Cobb MH (2001) Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr Rev 22:153-183
5. Kumar S, Boehm J, Lee JC(2003) p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases. Nat Rev Drug Discov 2:717-726
6. Hale KK, Trollinger D, Rihanek M, Manthey CL (1999) Differential expression and activation of p38 mitogen-activated protein kinase alpha, beta, gamma, and delta in inflammatory cell lineages. J Immunol 162:4246-4252
7. Kyriakis JM, Avruch J (2001) Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol Rev 81:807-869
8. Chen CY, Del Gatto-Konczak F, Wu Z, Karin M (1998) Stabilization of interleukin-2 mRNA by the c-Jun NH2-terminal kinase pathway. Science 280:1945-1949
9. Waetzig GH, Seegert D, Rosenstiel P, Nikolaus S, Schreiber S (2002) P38Mitogen-activated protein kinase is activated and linked to TNF-alpha signaling in inflammatory bowel disease. J Immunol 168:5342-5351
10. Badger AM, Bradbeer JN, Votta B, Lee JC, Adams JL, Griswold DE (1996) Pharmacological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function. J Pharmacol Exp Ther 279:1453-1461
11. Song GY, Chung CS, Jarrar D, Chaudry IH, Ayala A (2001) Evolution of an immune suppressive macrophage phenotype as a product of P38MAPK activation in polymicrobial sepsis. Shock 15:42-48
12. ten Hove T, van den Blink B, Pronk I, Drillenburg P, Peppelenbosch MP, van Deventer SJ (2002) Dichotomal role of inhibition of p38 MAPK with SB 203580 in experimental colitis. Gut 50:507-512
13. Hommes D, van den Blink B, Plasse T, Bartelsman J, Xu C, Macpherson B, Tytgat G, Peppelenbosch M, Van Deventer S (2002) Inhibition of stress-activated MAP kinases induces clinical improvement in moderate to severe Crohn's disease. Gastroenterology 122:7-14
14. Sandborn WJ, Faubion WA (2004) Biologics in inflammatory bowel diseases: how much progress have we made? Gut 53:1366-1373
15. Desreumaux P, Dubuquoy L, Nutten S, Peuchmaur M, Englaro W, Schoonjans K, Derijard B, Desvergne B, Wahli W, Chambon P, Leibowitz MD, Colombel JF, Auwerx J (2001) Attenuation of colon inflammation through activators of the retinoid X receptor (RXR)/peroxisome proliferator-activated receptor gamma (PPARgamma) heterodimer. A basis for new therapeutic strategies. J Exp Med 193:827-838
16. Philippe D, Dubuquoy L, Groux H, Brun V, Chuoi-Mariot MT, Gaveriaux-Ruff C, Colombel JF, Kieffer BL, Desreumaux P (2003) Anti-inflammatory properties of the mu opioid receptor support its use in the treatment of colon inflammation. J Clin Invest 111:1329-1338
17. Griswold DE, Hillegass LM, O'Leary-Bartus J, Lee JC, Laydon JT, Torphy TJ (1996) Evaluation of human cytokine production and effects of pharmacological agents in a heterologous system in vivo. J Immunol Methods 195:1-5
18. Appleyard CB, Wallace JL (1995) Reactivation of hapten-induced colitis and its prevention by anti-inflammatory drugs. Am J Physiol Gastrointest Liver Physiol 269:G119-G125
19. McCafferty DM, Wallace JL, Sharkey KA (1997) Effects of chemical sympathectomy and sensory nerve ablation on experimental colitis in the rat. Am J Physiol Gastrointest Liver Physiol 272:G272-G280
20. Ameho CK, Adjei AA, Harrison EK, Takeshita K, Morioka T, Arakaki Y, Ito E, Suzuki I, Kulkarni AD, Kawajiri A, Yamamoto S (1997) Prophylactic effect of dietary glutamine supplementation on interleukin 8 and tumour necrosis factor alpha production in trinitrobenzene sulphonic acid induced colitis. Gut 41:487-493
21. Yeow K, Phillips B, Dani C, Cabane C, Amri EZ, Derijard B (2001) Inhibition of myogenesis enables adipogenic trans-differentiation in the C2C12 myogenic cell line. FEBS Lett 506:157-162
22. Derijard B, Hibi M, Wu IH, Barrett T, Su B, Deng T, Barrett T, Deng T, Karin M, Davis RJ (1994) JNK1: a protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain. Cell 76:1025-1037
23. Dickens M, Rogers JS, Cavanagh J, Raitano A, Xia Z, Halpern JR, Greenberg ME, Sawyers CL, Davis RJ (1997) A cytoplasmic inhibitor of the JNK signal transduction pathway. Science 277:693-696
24. Han Z, Boyle DL, Chang L, Bennett B, Karin M, Yang L, Manning AM, Firestein GS (2001) c-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis. J Clin Invest 108:73-81
25. Desreumaux P, Brandt E, Gambiez L, Emilie D, Geboes K, Klein O, Ectors N, Cortot A, Capron M, Colombel JF (1997) Distinct cytokine patterns in early and chronic ileal lesions of Crohn's disease. Gastroenterology 113:118-126
26. Dohi T, Fujihashi K, Kiyono H, Elson CO, McGhee JR (2002) Mice deficient in Th1- and Th2-type cytokines develop distinct forms of hapten-induced colitis. Gastroenterology 119:724-733
27. Arulampalam V, Pettersson S (2002) Uncoupling the p38 MAPK kinase in IBD: a double edged sword? Gut 50:446-447
28. Kumar S, McDonnell PC, Gum RJ, Hand AT, Lee JC, Young PR (1997) Novel homologues of CSBP/p38 MAP kinase: activation, substrate specificity and sensitivity to inhibition by pyridinyl imidazoles. Biochem Biophys Res Commun 235:533-538
29. Tong L, Pav S, White DM, Rogers S, Crane KM, Cywin CL, Brown M, Pargellis CA (1997) A highly specific inhibitor of human p38 MAP kinase binds in the ATP pocket. Nat Struct Biol 4:311-316
30. Warny M, Keates AC, Keates S, Castagliuolo I, Zacks JK, Aboudola S, Qamar A, Pothoulakis C, LaMont JT, Kelly CP (2000) P38 MAP kinase activation by Clostridium difficile toxin A mediates monocyte necrosis, IL-8 production, and enteritis. J Clin Invest 105:1147-1156
31. Hollenbach E, Neumann M, Vieth M, Roessner A, Malfertheiner P, Naumann M (2004) Inhibition of p38 MAP kinase and RICK/NF-κB-signaling suppresses inflammatory bowel disease. FASEB 18:1550-1552
32. Borsch-Haubold AG, Pasquet S, Watson SP (1998) Direct inhibition of cyclooxygenase-1 and -2 by the kinase inhibitors SB 203580 and PD 98059. SB 203580 also inhibits thromboxane synthase. J Biol Chem 273:28766-28772
33. Morteau O, Morham SG, Sellon R, Dieleman LA, Langenbach R, Smithies O, Sartor RB (2000) Impaired mucosal defense to acute colonic injury in mice lacking cyclooxygenase-1 or cyclooxygenase-2. J Clin Invest 105:469-478
34. Guo X, Gerl RE, Schrader JW (2003) Defining the involvement of p38alpha MAPK in the production of anti- and proinflammatory cytokines using an SB 203580-resistant form of the kinase. J Biol Chem 278:22237-22242
35. Foey AD, Parry SL, Williams LM, Feldmann M, Foxwell BM, Brennan FM(1998) Regulation ofmonocyte IL-10 synthesis by endogenous IL-1 and TNF-alpha: role of the p38 and p42/44 mitogen-activated protein kinases. J Immunol 160:920-928
36. Bamba S, Andoh A, Yasui H, Makino J, Kim S, Fujiyama Y (2003) Regulation of IL-11 expression in intestinal myofibroblasts: role of c-Jun AP-1- and MAPK-dependent pathways. Am J Physiol Gastrointest Liver Physiol 285:G529-G538
37. Parrello T, Monteleone G, Cucchiara S, Monteleone I, Sebkova L, Doldo P, Luzza F, Pallone F (2000) Up-regulation of the IL-12 receptor beta 2 chain in Crohn's disease. J Immunol 165:7234-7239
38. Stallmach A, Marth T, Weiss B, Wittig BM, Hombach A, Schmidt C, Neurath M, Zeitz M, Zeuzem S, Abken H (2004) An interleukin 12 p40-IgG2b fusion protein abrogates T cell mediated inflammation: anti-inflammatory activity in Crohn's disease and experimental colitis in vivo. Gut 53:339-345